Prosonix Enters Collaboration With Imperial College London to Accelerate Development of Engineered Combination Respiratory Medicines (Multi-component Particles™, MCPs™)

Informations

• Publié par: prosonix
• Nombre de lectures: 17
• Langue: English

Extrait

Prosonix Enters Collaboration With Imperial

College London to Accelerate Development of

Engineered Combination Respiratory

Medicines (Multi-component Particles™,

MCPs™)

PR Newswire

OXFORD, England, July 5, 2012

OXFORD, England

,

July 5, 2012

/PRNewswire/ --

Prosonix (

Oxford, UK

) announced that it has signed a

Collaborative Research Agreement with Imperial

College London to accelerate the development of

engineered Multi-component Particles (MCPs™) as

respiratory medicines.

The collaboration will see Prosonix working closely with Dr Omar Usmani, an

internationally recognised expert in respiratory diseases and inhaled drug

delivery at the College's National Heart and Lung Institute (NHLI). Its aim is to

develop a deeper understanding of how MCPs can be translated into new

respiratory medicines with significant clinical benefits compared to existing

combination formulations in chronic obstructive pulmonary disease (COPD) and

asthma. Results from the Collaboration are intended to accelerate the

development of Prosonix' PSX2000 MCP Series of novel combination medicines,

with the aim of advancing one or more MCP candidates into formal

preclinical/proof of concept studies in 2013.

Prosonix' drug particle engineering approach and expertise has enabled the

development of MCPs that combine two active respiratory drug molecules

consistently in a pre-determined ratio in each and every particle in the

formulation, without the need for additional excipients. The scope of the

collaboration is to investigate MCPs in

in vitro

and

in vivo

models of the lung. It

will also compare key performance criteria, including synergistic effects in

reducing inflammation and improving bronchodilation resulting from co-

localisation of active drug components, with other combination formulations

including marketed combination products.

Excipient-free, drug-only MCPs engineered by Prosonix that will be evaluated in

the project include:

Inhaled corticosteroids (ICS) with long-acting beta-agonist (LABA), and

LABAs with long-acting muscarinic antagonists (LAMA)

David Hipkiss, Prosonix' CEO, said:

"Our strong links with the world's leading academic research groups focused on

respiratory medicine and inhaled drug delivery, such as Dr Omar Usmani's

group at Imperial College's NHLI and Professor Rob Price's team at the

University of Bath, alongside our own development team, ensure that Prosonix

retains a pre-eminent position in the field. We believe that our particle

engineering technology is potentially transformational in enabling the

development of novel inhaled combination therapies that deliver significant

clinical benefits. Following the recent second close of our £17.1M financing, we

believe we are very well placed now to drive the development of our unique

MCPs into the clinic."

Dr Omar Usmani said:

"

Co-localisation of active components in respiratory drug combinations in the

lung may offer the potential for an enhanced clinical effect and therapeutic

efficacythat is currently not fully achieved with current combinations.

With better treatment of respiratory diseases requiring improved combinations

for these reasons, we are extremely interested in Prosonix' particle engineering

approach and multi-component particles to determine whether

they can demonstrate clinical synergy and thus provide a novel and effective

means of delivering respiratory combinations."

Notes for Editors

About Prosonix

http://www.prosonix.co.uk

Prosonix is a speciality pharmaceutical company developing a portfolio of

inhaled respiratory medicines enabled by its state-of-the-art particle

engineering technology.

Its current development programmes include:

PSX1001, a drug-only directly substitutable generic version of fluticasone propionate, a

potent inhaled corticosteroid monotherapy for asthma in metered dose inhaler (pMDI);

PSX1002, a drug-only version of glycopyrrolate, a long-acting muscarinic antagonist for

chronic obstructive pulmonary disease (COPD) in pMDI, and

PSX2000 MCP™ Series, a potentially revolutionary approach to combination therapy

for respiratory diseases using Multi-component Particles™.

Prosonix' drug development is based on a novel ultrasonic particle engineering

approach. Its proprietary technology enables Prosonix to develop 'smart'

excipient-free, drug-only inhalable particles that are specifically designed to

optimally target the site of action in the lung, precisely and consistently,

delivering maximum clinical effect.

Prosonix has raised more than £20M from experienced life sciences investors

including Ventech, Gimv, Gilde Healthcare Partners, Enterpreneurs Fund, Quest

for Growth and Solon Ventures.

For more information, please contact:

David Hipkiss, CEO

[phone]

[e-mail]

Mark Swallow, Sita Shah, David Dible

Citigate Dewe Rogerson

[phone]

[e-mail]